University of Groningen

Cardiovascular effects of non-cardiovascular drugs in heart failure

Yurista, Salva

DOI:
[10.33612/diss.132706675](https://doi.org/10.33612/diss.132706675)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Yurista, S. (2020). *Cardiovascular effects of non-cardiovascular drugs in heart failure*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.132706675>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Cardiovascular effects of non-cardiovascular drugs in heart failure

Salva Reverentia Yurista

Salva Reverentia Yurista received a PhD scholarship from the Indonesia Endowment Fund for Education (LPDP), Ministry of Finance, Republic of Indonesia.

Financial support by the Graduate School of Medical Sciences and University of Groningen for the publication of this thesis is gratefully acknowledged.

Financial support by Dutch Heart Foundation for the publication of the thesis is gratefully acknowledged.

Additional financial support for the publication of this thesis was provided by ChipSoft B.V., Servier Nederland Farma B.V., Boehringer Ingelheim B.V. and Pfizer B.V.

Cardiovascular effects of non-cardiovascular drugs in heart failure

Copyright © 2020 Salva R. Yurista

All rights are reserved.

No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form by any means, without permission of the author.

Cover and layout design by: Iliana Boshoven- Gkini | www.AgileColor.com

Printing by: ProefschriftMaken

**rijksuniversiteit
 groningen**

Cardiovascular effects of non-cardiovascular drugs in heart failure

Proefschrift

ter verkrijging van de graad van doctor aan de
 Rijksuniversiteit Groningen
 op gezag van de
 rector magnificus prof. dr. C. Wijmenga
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 30 September 2020 om 09.00 uur

door

Salva Reverentia Yurista

geboren op 23 september 1990
 te Probolinggo, Indonesië

Promotores

Prof. dr. R.A. de Boer

Prof. dr. H.H.W. Silljé

Copromotor

Dr. B.D. Westenbrink

Beoordelingscommissie

Prof. dr. C. Maack

Prof. dr. J.F.C. Glatz

Prof. dr. A.A. Voors

Paranimfen

Tim Eijgenraam

Kirsten Nijholt

“It always seems impossible until it’s done” – Nelson Mandela

TABLE OF CONTENTS

Chapter 1	Introduction and aim of the thesis	11
Chapter 2	Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction <i>European Journal of Heart Failure</i> . 2019 Jul;21(7):862-873.	19
Chapter 3	Effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on renal structure and function in non-diabetic rats with left ventricular dysfunction after myocardial infarction <i>Cardiovascular Drugs and Therapy</i> . 2020 Jun;34(3):311-321	47
Chapter 4	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? <i>Cardiovascular Diabetology</i> . 2020 Jan 7;19(1):5	69
Chapter 5	Factor Xa inhibition with apixaban does not influence cardiac remodelling in rats with heart failure after myocardial infarction <i>Cardiovascular Drugs and Therapy</i> . 2020 may 26. <i>online ahead of print</i>	81
Chapter 6	Ketone ester treatment improves cardiac function and reduces pathologic remodeling in pre-clinical models of heart failure <i>Manuscript in submission</i>	101
Chapter 7	Ketone bodies: potential therapeutic use in cardiovascular disease <i>Manuscript in preparation</i>	129
Chapter 8	Summary and future perspectives	149
Appendices	Dutch summary	160
	Acknowledgements	164
	Bibliography	167
	Curriculum vitae	169